The financial stakes in Amgen Inc.’s race to develop a new kind of cholesterol-lowering drug are high and, perhaps as much as any other state, Rhode Island is invested in the outcome.
The state’s largest biotechnology employer, Amgen began manufacturing AMG 145, which is currently in the third phase of clinical trials for federal approval, in its West Greenwich plant last year.
The drug is a monoclonal antibody derived from a rare, mutated gene that helps clear cholesterol from the body.
Amgen and their competitors hope the new drug will replace statins, the wildly lucrative anti-cholesterol drugs that gained widespread use to combat heart disease starting in the 1990s.
Lipitor, a statin made by Pfizer Inc., is considered the best-selling drug in pharmaceutical history, with $125 billion in sales, but like most statins its patent recently expired.
If the new class of drugs is proven safe and effective enough for U.S. Food and Drug Administration approval, pharmaceutical companies see potential sales in the billions.
Even if the remaining clinical trials go well, the drug is still likely at least a year or two away from being marketed to the general public, but most of the country’s major drug companies are pursuing it.
Based on the progress of their trials, Amgen is considered a current front-runner, along with a joint effort from Tarrytown, N.Y.-based Regeneron Pharmaceuticals Inc. and Sanofi of France. Pfizer Inc. of New York City is also developing a version of the drug.
Partly based on the potential of drugs in the pipeline, Amgen’s stock in August had risen more than 20 percent since the start of the year.
Based in the Bay Area-city of Mountain View, Calif., Amgen in late 2011 began a $70 million investment in the West Greenwich plant for “pipeline readiness for AMG 145 and other projects,” said Amgen spokeswoman Christine Regan in an email.
It’s unclear whether Amgen would make all of its AMG 145 in West Greenwich if the drug is approved, as the company also has factories in Colorado and Puerto Rico capable of making it.
But if the drug becomes the blockbuster many expect, it could provide a significant boost for Rhode Island’s stagnant economy.
Join PBN and two panels of successful female executives, business owners and entrepreneurs as we delve into what women should do to advance their careers, and become leaders in the corporate world and their own enterprises.
PBN's annual Book of Lists has been an essential resource for the local business community for almost 30 years. The Book of Lists features a wealth of company rankings from a variety of fields and industries, including banking, health care, real estate, law, hospitality, education, not-for-profits, technology and many more.